PARDES BIOSCIENCES, INC.

Pardes Biosciences, Inc. (PRDS) is a clinical-stage antiviral biopharmaceutical company that entered the public markets in 2021 through a merger with LifeSci Acquisition 2 Corp, a blank-check vehicle sponsored by LifeSci Capital LLC. The company operates in the biotechnology and life sciences sector, with its pipeline concentrated on oral antiviral therapeutics targeting respiratory viruses, including SARS-CoV-2. The amended quarterly report (Form 10-Q/A) filed November 23, 2021, captures the company's early post-merger period as a reporting public entity. Pardes's lead program focused on protease inhibitor compounds aimed at treating infectious diseases. Sign up at SpacDesk for complete filing histories, sponsor profiles, and deal analytics covering PRDS and hundreds of additional SPAC transactions.